Targovax
Thomas Hansen has over 15 years of experience in academic research. Before joining Targovax he worked as an assistant professor at Aarhus University where he led a research team focusing on RNA biology and bioinformatics. In 2011, Thomas Hansen pioneered the discovery of circular RNA in human cells, and later in 2013 published the first functional characterization of circular RNA in Nature.
This person is not in any teams
This person is not in any offices
Targovax
Targovax (OSE: TRVX) is a clinical-stage biotechnology company developing immune activators to target hard-to-treat solid tumors.